Navigation Links
Sangamo BioSciences Presents Clinical Data From Key SB-728-T HIV Studies: Proof Of Concept For Ongoing Sustained Functional Control Of HIV Viral Load; Cytoxan Preconditioning Successfully Enhances Engraftment
Date:12/6/2013

RICHMOND, Calif., Dec. 6, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of data from all dose cohorts in the Company's ongoing clinical trials (SB-728-1101 and SB-728-902 Cohort 5) of SB-728-T, which is being developed for the functional control of HIV/AIDS. The data are being presented at the Sixth International Workshop on HIV Persistence during Therapy, considered to be the reference workshop on HIV reservoirs and eradication strategies, which is being held in Miami, FL, December 3-6 2013.

(Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO)

"The results announced today represent a major milestone," stated Geoff Nichol, M.B., Ch.B., Sangamo's executive vice president of research and development. "We have succeeded in achieving sustained control of HIV with SB-728-T in CCR5 delta-32 heterozygotes, and we have shown that we can safely use Cytoxan to potentially achieve threshold levels of engraftment for all patients with HIV. Collectively, data from our clinical studies suggest that protection of CD4 T-cells by ZFN mediated CCR5 disruption may provide helper function to CD8 cells enabling the immune system to mount an anti-HIV response that can also erode the HIV reservoir.  The reservoir is a compartment of the HIV-infected immune system that is not addressed by antiretroviral medication and its depletion is key to the goal of complete eradication of HIV infection."

Sangamo's Phase 1 data suggested that if a threshold level of engraftment of SB-728-T was achieved, specifically of CD4 cells fully protected from HIV entry by zinc finger nuclease (ZFN)-mediated modification of both CCR5 genes (biallelic modification), then functional contr
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Sangamo BioSciences Reports Second Quarter 2012 Financial Results
2. Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
3. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
4. Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference
5. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
6. Sangamo BioSciences Announces First Quarter 2013 Conference Call and Webcast
7. Sangamo BioSciences Reports First Quarter 2013 Financial Results
8. Sangamo BioSciences Announces Second Quarter 2013 Conference Call And Webcast
9. Sangamo BioSciences Announces Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome
10. Sangamo BioSciences Reports Second Quarter 2013 Financial Results
11. Sangamo BioSciences Announces Notice Of Allowance For New Patent Application Covering Genome Modification Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... ,  July 22, 2014 ... of Thomson Reuters , the world,s leading ... professionals, today announced Cortellis Clinical Trials ... marked an industry-first milestone with the documentation ... providing pharmaceutical professionals with greater and quicker ...
(Date:7/22/2014)...  Neurotrope Bioscience, Inc., a subsidiary of Neurotrope, Inc. ... with the Icahn School of Medicine at ... ) to utilize its proprietary information and data package ... Niemann-Pick Type C Disease (NPC), a rare disease, mostly ... license also covers other diseases and disorders relying on ...
(Date:7/22/2014)... 22, 2014 The steady decline of ... to previously rep-friendly specialties, according to the spring ... consulting firm ZS Associates.      AccessMonitor™ ... pharmaceutical sales teams. The report examines how often ... the pharmaceutical sales reps who visit their offices. ...
Breaking Medicine Technology:Thomson Reuters Cortellis Clinical Trials Intelligence Reaches Industry Milestone with 180,000 Clinical Trials 2Thomson Reuters Cortellis Clinical Trials Intelligence Reaches Industry Milestone with 180,000 Clinical Trials 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 2Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 4Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 5Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 2Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 3Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 4Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 5
... Findings from an international,multicenter, randomized, double-blind, placebo-controlled Phase ... of moderate to severe,plaque psoriasis will be presented ... the World Congress of Dermatology, which takes place ... Aires, Argentina. The presentation, entitled CNTO 1275 ...
... Study Will Assess Drug,s Benefit, Alone and With Lipitor(R), ... Cholesterol and Triglycerides -, HAYWARD, Calif., Sept. 25 ... and development of novel,therapeutics for diabetes and related metabolic ... 2 trial of MBX-8025 in overweight or,obese patients with ...
Cached Medicine Technology:Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting 2Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia 2
(Date:7/22/2014)... HealthDay Reporter TUESDAY, July 22, ... help predict survival and the course of the disease in ... disease, Italian researchers report. , , The components in the ... progressing are called albumin and creatinine. These components are normally ... U.S. National Library of Medicine. But now it appears ...
(Date:7/22/2014)... a five-year, $3 million grant to study how ... maltreatment during childhood leave molecular marks in DNA ... The Center for Biomarker Research and Personalized Medicine ... with Duke University School of Medicine, will conduct ... National Institutes of Health, National Institute of Mental ...
(Date:7/22/2014)... radio-frequency identification (RFID) tags to hundreds of individual honey bees ... discoveries: Some foraging bees are much busier than others; and ... , The findings are reported in the journal ... about 20 percent of the foraging bees in a hive ... gathered to feed the hive. , "We found that some ...
(Date:7/22/2014)... Diego, CA (PRWEB) July 22, 2014 Today, ... geared toward teens ages 13 – 18 to help increase ... by specially trained therapists, teens will learn how to make ... “Adolescence is a time of excitement and adventure, but also ... Perper, Ph.D. and founder of Therapy Changes . , ...
(Date:7/22/2014)... Thought Technology's new Stress Control ... to help clinicians do biofeedback therapy with clients, even ... The tools in the suite assess a client's physiological ... to teach them to recuperate from stress using biofeedback. ... with stress and its negative impact on our health. ...
Breaking Medicine News(10 mins):Health News:Blood Test Might Help Predict Survival With Lou Gehrig's Disease 2Health News:Blood Test Might Help Predict Survival With Lou Gehrig's Disease 3Health News:VCU receives grant to study molecular marks left by childhood adverse experiences 2Health News:Radio frequency ID tags on honey bees reveal hive dynamics 2Health News:Therapy Changes Announces Teen Support Group Therapy 2Health News:Thought Technology to Present Software for Stress Control at the 2014 American Psychological Association Convention in DC 2Health News:Thought Technology to Present Software for Stress Control at the 2014 American Psychological Association Convention in DC 3
... SUNDAY, May 30 (HealthDay News) -- A study in mice ... in humans, scientists say. , Women may begin taking part ... year, they added. , "We believe that this vaccine will ... in the same way that vaccines have prevented many childhood ...
... identified the genetic cause of an inherited condition that ... geneticists at the UCSD Institute for Genomic Medicine, together ... and England, should allow couples at risk of conceiving ... to be identified beforehand through genetic screening. The ...
... A 17-year-long community study looking at symptoms of enlarged ... suggests that surgery for benign prostatic hyperplasia ... treatment from drug-based therapy, according to a new study by ... at the annual meeting of the American Urological Association ...
... feet first in shallow or unfamiliar waters, experts say , ... the age of 14 are hospitalized each year because of ... in a severe spinal cord injury, researchers say. , To ... to use caution near any body of water and to ...
... ... announce the launch of his brand-new blog, LaceFrontWigReview.com. Developed to complement his original website, ... Visit the web store to discover a luxurious selection of full-lace remy and virgin ... ...
... United States military recruits ... ... United States military is a life-long dream but a dream that unfortunately is being denied to ... Spa , with three locations in Pittsburgh, PA is now making laser tattoo removal ...
Cached Medicine News:Health News:Faulty gene stops cell 'antennae' from transmitting 2Health News:Research finds surgery outperforms drug therapy in treatment of benign prostatic hyperplasia 2Health News:Dive Safely -- Or Risk Spinal Cord Damage 2Health News:SassySecret.com Debuts Interactive Blog to Provide Wig Care and Application Tips 2Health News:The Skin Center Medical Spa in Pittsburgh Helps Military Recruits Meet Enlisting Requirements 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: